Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The price of Pfizer Inc (NYSE: PFE) closed at $25.29 in the last session, up 0.04% from day before closing price of $25.28. In other words, the price has increased by $0.04 from its previous closing price. On the day, 42.9 million shares were traded. PFE stock price reached its highest trading level at $25.56 during the session, while it also had its lowest trading level at $25.13.
Ratios:
We take a closer look at PFE’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.60 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.86. For the most recent quarter (mrq), Quick Ratio is recorded 0.97 and its Current Ratio is at 1.28. In the meantime, Its Debt-to-Equity ratio is 0.66 whereas as Long-Term Debt/Eq ratio is at 0.62.
On November 13, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $30.Scotiabank initiated its Sector Outperform rating on November 13, 2025, with a $30 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 23 ’25 when Dolsten Mikael bought 59,781 shares for $23.09 per share.
Dolsten Mikael bought 55,000 shares of PFE for $1,312,736 on May 05 ’25. On Mar 04 ’25, another insider, DAMICO JENNIFER B., who serves as the SVP & Controller of the company, sold 2,500 shares for $25.93 each. As a result, the insider received 64,825 and left with 11,850 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PFE now has a Market Capitalization of 143791554560 and an Enterprise Value of 191038537728. As of this moment, Pfizer’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.74, and their Forward P/E ratio for the next fiscal year is 8.46. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.29 while its Price-to-Book (P/B) ratio in mrq is 1.55. Its current Enterprise Value per Revenue stands at 3.043 whereas that against EBITDA is 7.811.
Stock Price History:
The Beta on a monthly basis for PFE is 0.43, which has changed by -0.053892195 over the last 52 weeks, in comparison to a change of 0.1877265 over the same period for the S&P500. Over the past 52 weeks, PFE has reached a high of $27.69, while it has fallen to a 52-week low of $20.92. The 50-Day Moving Average of the stock is 0.41%, while the 200-Day Moving Average is calculated to be 3.39%.
Shares Statistics:
According to the various share statistics, PFE traded on average about 63.46M shares per day over the past 3-months and 36690850 shares per day over the past 10 days. A total of 5.69B shares are outstanding, with a floating share count of 5.68B. Insiders hold about 0.09% of the company’s shares, while institutions hold 66.90% stake in the company. Shares short for PFE as of 1765756800 were 139486093 with a Short Ratio of 2.20, compared to 1763078400 on 130660363. Therefore, it implies a Short% of Shares Outstanding of 139486093 and a Short% of Float of 2.4500001.
Dividends & Splits
The forward annual dividend rate for PFE is 1.72, which was 1.7 in the trailing 12 months. Against a Trailing Annual Dividend Yield of 0.06724683. The stock’s 5-year Average Dividend Yield is 4.87. . The current Payout Ratio is 120.11% for PFE, which recently paid a dividend on 2025-11-07 with an ex-dividend date of 2026-01-23. Stock splits for the company last occurred on 2020-11-17 when the company split stock in a 1054:1000 ratio.
Earnings Estimates
. The current market rating for Pfizer Inc (PFE) reflects the collective analysis of 17.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.75, with high estimates of $0.92 and low estimates of $0.67.
Analysts are recommending an EPS of between $3.29 and $3.0 for the fiscal current year, implying an average EPS of $3.13. EPS for the following year is $2.99, with 25.0 analysts recommending between $3.3 and $2.8.
Revenue Estimates
According to 16 analysts, . The current quarter’s revenue is expected to be $16.91B. It ranges from a high estimate of $17.7B to a low estimate of $16.13B. As of . The current estimate, Pfizer Inc’s year-ago sales were $17.76BFor the next quarter, 16 analysts are estimating revenue of $13.98B. There is a high estimate of $14.52B for the next quarter, whereas the lowest estimate is $13.6B.
A total of 21 analysts have provided revenue estimates for PFE’s current fiscal year. The highest revenue estimate was $62.7B, while the lowest revenue estimate was $61.15B, resulting in an average revenue estimate of $61.97B. In the same quarter a year ago, actual revenue was $63.63BBased on 23 analysts’ estimates, the company’s revenue will be $61.06B in the next fiscal year. The high estimate is $62.79B and the low estimate is $59.86B.
